NeoGenomics (NEO) Stock: Buy, Sell, or Hold?
$16.54
-0.29 (-1.72%)
âŧ
5d:
+0.3%
30d:
-2.01%
90d:
+3.76%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Oct 28, 2026
0d
Protect NEO Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (50%)
Quality Score
44/100
Position
FAIR
30-Day Fair Range
$16.24 â $17.67
Position: FAIR
Forward P/E & Valuation
52.6x
STRETCHED
vs 44.4x historical avg
Wall Street Target
$23.40
+41.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$15.90 / $18.15
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: NEO is fairly priced but lacks strong directional signals. At 5.8% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Get Alerted When NEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.32
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.51
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NEO is currently trading at $16.54, which is considered fair relative to its 30-day fair value range of $16.24 to $17.67. From a valuation perspective, the stock is trading at a premium (Forward PE: 52.6) compared to its historical average (44.4). At these levels, the market is pricing in 5.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NEO is in a uptrend. Immediate support is located at $15.90, while resistance sits at $18.15.
Market Sentiment: NEO scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.40 (+41.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NEO is in a uptrend. Immediate support is located at $15.90, while resistance sits at $18.15.
Market Sentiment: NEO scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.40 (+41.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$16.24 -
$17.67
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
Trading Range & Key Levels
30-Day Trading Range
$16.24 -
$17.67
Current vs Trading Range
FAIR
Support Level
$15.90
Resistance Level
$18.15
Current Trend
Uptrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding NEO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.5% below Wall St target ($23.40)
- NEUTRAL: PE elevated vs history but 5.8% growth expectation is conservative given 131% recent growth
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
52.57
Wall Street Target
$23.40
(+41.5%)
Revenue Growth (YoY)
11.4%
Earnings Growth (YoY)
130.6%
Profit Margin
-4.1%
Valuation Premium vs History
+5.8% premium
PE vs Historical
52.6 vs 44.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.8%
(market-implied from PE analysis)
1-Year Target
$17.50
(+6%)
2-Year Target
$18.51
(+12%)
3-Year Target
$19.59
(+18%)
3-Yr Target (if PE normalizes)
(PE: 53â44)
PE COMPRESSION
$16.54
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 52.6, Growth: 54.2%)
$55.82
(+238%)
Base:
(SPY PE: 19.9, Growth: 54.2%)
$21.09
(+28%)
Bear:
(PE: 16.9, Growth: 54.2%)
$17.92
(+8%)
Share NEO Analysis
Share this live NEO analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NEO)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 29, 2026
Daily AI digest
AI Retail Discussion Summary:
NeoGenomics reported Q3 earnings of $0.07 per share, surpassing estimates by 26.2%, and generated revenue of $209.3 million. The company expects full-year earnings in the range of 21 cents to 22 cents per share.
Key Retail Themes:
earnings surprise
revenue growth
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 3:14 AM ET
Data refreshes hourly during market hours. Next update: 4:14 AM
Data refreshes hourly during market hours. Next update: 4:14 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$201 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
23 analysts |
$416 | 67 BUY |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
27 analysts |
$752 | 48 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
24 analysts |
$260 | 50 HOLD |
Advanced NEO Option Strategies
Professional options setups generated by AI based on today's NEO price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NEO Research Pages
